Solid tumor
Conditions
Interventions
Observation Group:None
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 years old, gender is not limited; 2.Patients with solid tumors diagnosed by histology or pathology, including but not limited to lung cancer, colorectal cancer and liver cancer; 3.ECOG PS score: 0-3; 4.At least one measurable lesion (according to RECIST 1.1 criteria); 5.Patients treated after January 1, 2023 with two or more cycles of bevacizumab combination regimen;
Exclusion criteria
Exclusion criteria: 1.Persons with proven hypersensitivity to bevacizumab and its excipients; 2.Pregnant or lactating women; 3.Persons who, in the judgment of the investigator, have other factors that make them unsuitable for inclusion in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| drug-related AEs;abnormal laboratory test values;serious adverse events (SAEs);Incidence and severity of adverse events (AEs); | — |
Secondary
| Measure | Time frame |
|---|---|
| (progression-free survival;PFS);(Objective Response Rate;ORR);(Disease Control Rate;DCR); | — |
Countries
China
Contacts
Public ContactWang Xin
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed